Members | Facebook | Twitter
Date: August 25, 2021 | 12:00 - 1:00pm EDT Zoom Registration Link: https://bostonu.zoom.us/meeting/register/tJYud-uvrDkrE90KBJOGKgj6eDaIDsI76qZ0
Learning Objectives:
1. Explore the changing paradigm of AA and AD disease presentation and treatment approach.
2. Assess and interpret the latest clinical trial data among emerging oral agents in AA and/or AD and terms of therapeutic target, safety, efficacy, and tolerability
3. Recognize the potential place in therapy and monitoring aspects for the emerging agents in AD and AA in order to effectively engage patients in shared decision-making for their treatment plan.
4. Outline a plan to proactively identify and remove barriers for health maintenance services and medication access in underserved patients with AA and/or AD.
Target Audience
This curriculum is intended for a broad audience of community pharmacists, dermatologic specialty pharmacists, and managed care professionals involved in the care and treatment of patients with AD and/or AA.
Speakers
Amanuel Kehasse, PharmD, PhDCourse Director Clinical Pharmacy Specialist in Autoimmune and Interstitial lung disease Boston Medical Center Health System Boston, MA
Peter A Lio, MD Assistant Professor of Clinical Dermatology and Pediatrics Northwestern Feinberg School of Medicine Director, Chicago Integrative Eczema Center Founding Partner Medical Dermatology Associates of Chicago Chicago, IL
Accreditation
The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This is an application-based educational activity. Pharmacists will receive 1.0 contact hours (0.10 ceus) for the educational activity. No partial credit is available. ACPE Universal Activity Number (UAN): 0060-9999-21-023-L01-P
ACCMEBoston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Boston University School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcknowledgementThis activity is presented by Boston University School of Medicine and The University of Rhode Island College of Pharmacy and is supported by and independent educational grant from Pfizer.
RISHP Showcase
Table & Sponsorship Options
Karen Nolan
For website issues issues, please click here
